Received Feb 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| FLUX | INFLUENZA (SEASONAL) (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Both injection sites were tender for 2-3 days; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site tenderness in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Co-suspect products included INFLUENZA VACCINE for prophylaxis and COVID-19 VACCINE for prophylaxis. On an unknown date, the patient received Shingles vaccine, INFLUENZA VACCINE and COVID-19 VACCINE. On an unknown date, an unknown time after receiving Shingles vaccine and an unknown time after receiving INFLUENZA VACCINE and COVID-19 VACCINE, the patient experienced injection site tenderness (Verbatim: Both injection sites were tender for 2-3 days). The outcome of the injection site tenderness was resolved (duration 3 days). It was unknown if the reporter considered the injection site tenderness to be related to Shingles vaccine. It was unknown if the company considered the injection site tenderness to be related to Shingles vaccine. Additional Information: GSK receipt date: 28-JAN-2026 This case was reported by a patient via interactive digital media. The patient reported as nothing was worse than getting flu and covid shots in the opposite arm. The patient did three at once. Both injection sites were tender for 2-3 days. The batch number was not provided, and we are unable to contact the reporter.